Insulin and Blood Sugar in Pregnancy Planning: What You Need to Know Before You Conceive

Insulin is a hormone, and also a class of prescription medications (human insulin and analogs such as NPH, regular insulin, insulin lispro, insulin aspart, and insulin detemir) used to manage type 1 diabetes, type 2 diabetes, and gestational diabetes. Metformin, GLP-1 receptor agonists (semaglutide, liraglutide), and SGLT2 inhibitors are separate oral or injectable diabetes drug classes with very different pregnancy safety profiles. This article is about preparing blood sugar control and medication regimens before conception, not about diagnosing or dosing any individual person.

The useful question for someone with diabetes who is planning a pregnancy is not "is my blood sugar under control" but "will my glucose be in a safe range during the specific weeks when the embryo's organs are forming, most of which happen before a positive pregnancy test." A stable HbA1c below 6.5% for at least three months before conception is the target used by major diabetes and endocrine guidelines because organogenesis is largely complete by eight weeks of gestation, often before pregnancy is confirmed. Insulin is the glucose-lowering medication with the longest and most consistent pregnancy safety record; several oral and injectable diabetes drugs, including GLP-1 agonists and SGLT2 inhibitors, are not recommended in pregnancy and should be addressed with a prescriber before trying to conceive, not after a positive test.

Why preconception control matters more than pregnancy control alone

Once a pregnancy test is positive, the embryo's heart, neural tube, and major organs have often already begun forming or will finish forming within days to a few weeks. This is why diabetes guidelines, including the American Diabetes Association's Standards of Care, emphasize preconception counseling for all women of reproductive age with diabetes, rather than counseling that begins at the first prenatal visit. Elevated glucose during early organogenesis is associated with a higher rate of major congenital malformations and early pregnancy loss in observational and registry data; the magnitude of that risk rises with higher periconceptional HbA1c, though exact relative-risk figures vary across studies and should be checked against the primary literature rather than quoted as a fixed multiplier.

Insulin does not cross the placenta in clinically meaningful amounts, which is the core reason it is preferred over other glucose-lowering drugs across all trimesters. This is an established pharmacologic property, not a claim specific to any single brand of insulin.

What HbA1c target, and how long it realistically takes

Guidelines commonly cite a target HbA1c below 6.5% sustained for at least three consecutive months before attempting conception, individualized to avoid frequent or severe hypoglycemia, which carries its own risks to both the pregnant person and the pregnancy. Because red blood cells live roughly three months, HbA1c reflects average glucose over that period, so a person starting from a much higher HbA1c should plan for a longer runway, often several months, rather than expecting rapid results from a single medication change.

A continuous glucose monitor (CGM) is widely recommended before and during pregnancy for people with type 1 diabetes because it shows glucose trends that a fingerstick or quarterly HbA1c cannot. Large randomized trial data in pregnant people with type 1 diabetes support CGM use for improving neonatal outcomes; specific effect sizes reported in any single trial should be verified against the original publication before being repeated as an exact figure.

Which medications continue, which stop, and why

Diabetes medications differ sharply in their pregnancy evidence base, and this is where preconception planning changes practical decisions the most.

Insulin (NPH, regular human insulin, insulin lispro, insulin aspart, insulin detemir). This class has the longest track record in pregnancy and is generally continued or initiated as the primary glycemic treatment. Differences between specific insulin analogs (for example, aspart versus regular human insulin, or detemir versus NPH) have been studied in randomized trials for hypoglycemia rates and neonatal outcomes; the choice between them is a discussion for the prescribing endocrinologist based on the specific insulin, the person's hypoglycemia history, and local trial data, not a decision to make unsupervised.

Metformin. Metformin crosses the placenta. Trial data comparing metformin with insulin in gestational diabetes have generally shown similar short-term neonatal outcomes, though a meaningful proportion of metformin-treated patients required supplemental insulin. Metformin is sometimes continued into early pregnancy for polycystic ovary syndrome (PCOS)-related fertility management, but insulin is typically added or substituted once glucose control is the goal, per most current guidance. This is an area of ongoing practice variation, and metformin's pregnancy safety data are less extensive than insulin's.

GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, liraglutide/Victoza, and related drugs). Current FDA labeling advises against use in pregnancy, based on animal reproductive toxicity data and the absence of adequate human safety data. Guidance from prescribers commonly recommends stopping these medications a defined period before attempting conception; the exact washout interval should come from the current FDA label and the prescribing endocrinologist rather than a fixed rule repeated across sources, since labeling has been updated over time.

SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin). The FDA has issued safety communications regarding SGLT2 inhibitor use, and these drugs are not recommended in pregnancy planning or during pregnancy. They should be stopped before conception in coordination with the prescriber, with a switch to insulin or another pregnancy-appropriate option.

ACE inhibitors, ARBs, and statins. ACE inhibitors and ARBs, often used for diabetic kidney disease or blood pressure control, are fetotoxic beyond the first trimester and are typically switched to a pregnancy-compatible antihypertensive (such as labetalol or nifedipine) before conception. Statins are not used in pregnancy. Stopping either class should be planned with the prescriber managing the underlying condition, since abrupt discontinuation of an antihypertensive or a kidney-protective agent carries its own risks that need monitoring.

Blood glucose targets during pregnancy differ from standard type 2 diabetes goals

Pregnancy lowers fasting glucose and blunts glucose swings even in people without diabetes, so non-pregnancy glucose targets are not appropriate once pregnancy begins. Guidelines such as the UK's NICE NG3 and the ADA Standards of Care describe tighter goals than standard adult diabetes management: lower fasting glucose targets and lower post-meal targets than are typically used outside pregnancy. The rationale is that maternal glucose above these tighter thresholds drives fetal hyperinsulinism, which is linked to larger birth weight, higher Caesarean and shoulder dystocia rates, and neonatal hypoglycemia after birth.

Hypoglycemia is a real and separate risk during intensive pregnancy glucose management. Significant maternal hypoglycemia triggers a stress hormone response that can affect uteroplacental blood flow. People using intensive insulin regimens in pregnancy are generally advised to keep a fast-acting glucose source available and to set CGM low alerts at a level their care team recommends, which is often higher than the low-alert setting used outside pregnancy.

A decision framework for the months before conception

This is not individualized medical advice. It is a structure for the conversation to have with an endocrinologist or maternal-fetal medicine specialist, organized around the facts that actually change the plan.

Step 1: Where is the HbA1c right now, and what does that mean for timeline?

• Below 6.5%, stable for three months: conception can reasonably be discussed now, alongside medication review.
• 6.5% to 8%: expect a runway of a few months of active titration before the three-month stable window can be achieved.
• Above 8%: expect a longer runway, often six months or more, and prioritize contraception until the target is closer, since an unplanned conception at this level carries materially higher risk during organogenesis.

Step 2: Which current medications are contraindicated or discouraged in pregnancy?

• GLP-1 agonist, SGLT2 inhibitor, ACE inhibitor/ARB, or statin on the medication list: flag each one by name to the prescriber now, not after conception. Each has a different required lead time and a different replacement strategy.
• Metformin alone for PCOS: discuss whether it continues, and at what point insulin is added if glucose control becomes the goal.

Step 3: What is not yet on the medication list but might be needed?

• If insulin has never been used and glucose remains above target on oral agents, expect insulin initiation to be part of the preconception plan, not a pregnancy-only intervention.
• If a CGM has never been used, ask whether starting one now, before conception, is appropriate; this is standard practice for type 1 diabetes in most current guidance.

Step 4: What baseline testing has not been done yet?

• Renal function (creatinine, eGFR, urine albumin-to-creatinine ratio), TSH, retinal exam, and lipid panel are commonly recommended before conception in people with pre-existing diabetes, particularly type 1 diabetes or longer-standing type 2 diabetes.
• A retinal exam matters specifically because rapid glycemic improvement from a high baseline has been associated with transient worsening of diabetic retinopathy; a preconception baseline lets an ophthalmologist tell pregnancy-related change from coincidental change.

Step 5: When does this go from "primary care" to "specialist co-management"?

• eGFR below 60 mL/min/1.73m², proliferative retinopathy, prior severe hypoglycemia, or an HbA1c that is not moving despite adjustment are reasons to involve an endocrinologist and, for renal disease, a nephrologist before continuing to try to conceive.

Special populations: what changes, and what does not

Older parents planning a later pregnancy

Gestational diabetes risk rises with maternal age, and pregnancy after 35 is associated with a higher chance of entering pregnancy with undiagnosed impaired glucose tolerance or type 2 diabetes. For this reason, some guidelines recommend an oral glucose tolerance test at the first prenatal visit for older individuals with risk factors, rather than waiting for the standard mid-pregnancy screen. An HbA1c in the prediabetes range before conception is a reasonable trigger for dietitian referral and closer preconception monitoring rather than a wait-and-see approach.

Adolescents and young adults with type 1 diabetes

Because a substantial share of pregnancies are unplanned, preconception counseling and contraceptive discussion are recommended once a teenager with type 1 diabetes becomes sexually active, not only when pregnancy is being actively planned. Insulin needs can rise across the menstrual cycle, particularly in the luteal phase, and tracking cycle phase alongside CGM data can help anticipate those swings. A qualitative study of women with type 1 diabetes describing their postnatal experiences and views on future pregnancies found that many wanted earlier, more specific preconception guidance than they received, which supports building this conversation into routine diabetes care well before a pregnancy is planned (Postnatal experiences and perspectives on future pregnancies among women with type 1 diabetes, 2026).

Diabetic kidney disease

As kidney function declines, insulin clearance slows, because the kidney is a site of insulin degradation. This means the same insulin dose can produce a larger and longer glucose-lowering effect as eGFR falls, raising hypoglycemia risk unless doses are adjusted. Pregnancy itself causes a temporary rise in glomerular filtration rate that can mask underlying kidney disease severity in early pregnancy; in more advanced pre-pregnancy kidney disease, this masking can be followed by accelerated decline in kidney function that does not always fully reverse after delivery. Metformin is avoided at more advanced kidney impairment because of lactic acidosis risk, and SGLT2 inhibitors lose glucose-lowering efficacy and are not appropriate at lower eGFR levels regardless of pregnancy plans. Nephrology co-management is commonly recommended for anyone with reduced kidney function who is planning conception.

Folic acid and preconception labs

General guidance for the population is 400 micrograms of folic acid daily before conception. People with pre-existing diabetes are commonly advised to take a substantially higher dose, because neural tube defect risk is elevated in hyperglycemic pregnancies; the exact recommended dose and start timing should be confirmed with the prescriber, since this is a case where getting the number right matters and generic web guidance is not a substitute for a current label or guideline check.

Autoimmune thyroid disease is more common in type 1 diabetes than in the general population, and untreated thyroid dysfunction around conception is linked to higher miscarriage risk, which is why checking TSH before conception is commonly recommended for this group.

Reasonable baseline testing before conception in a person with pre-existing diabetes commonly includes HbA1c, fasting glucose and an oral glucose tolerance test if HbA1c is borderline, kidney function testing, TSH, a lipid panel, a retinal exam, and blood pressure assessment. The specific panel should be set by the prescriber based on diabetes type, duration, and existing complications.

Gestational diabetes: what changes after delivery

Gestational diabetes (GDM) is diagnosed in a meaningful minority of pregnancies in the United States; the CDC tracks and publishes current national estimates (CDC, Gestational Diabetes). First-line treatment is nutrition therapy, with insulin added if glucose targets are not met. Insulin needs from gestational diabetes typically resolve quickly after delivery as placental hormones clear, but this does not mean the underlying glucose tolerance issue is gone. A minority of people with GDM are found to have overt type 2 diabetes at postpartum testing, and a larger share have impaired glucose tolerance, which is why a postpartum oral glucose tolerance test, generally done six to twelve weeks after delivery, is recommended regardless of how quickly insulin needs dropped.

A study following metabolic outcomes at twelve months postpartum among people with glucose intolerance in pregnancy found that a portion continue to have measurable glucose abnormalities well beyond the immediate postpartum window, supporting ongoing testing rather than a single postpartum check (Metabolic outcomes at 12 months postpartum among individuals with glucose intolerance in pregnancy, 2026). Exact recurrence and progression percentages vary across cohorts and should be checked against the specific study population before being quoted as a universal figure.

What is established, what is plausible, and what is not established

Established: insulin does not meaningfully cross the placenta and is the preferred glucose-lowering drug across pregnancy; a preconception HbA1c near or below 6.5% is associated with lower rates of major congenital anomalies compared with poorly controlled diabetes at conception; GLP-1 agonists and SGLT2 inhibitors are not currently recommended in pregnancy per FDA labeling and safety communications; ACE inhibitors, ARBs, and statins are not used in pregnancy; gestational diabetes carries a meaningfully elevated risk of later type 2 diabetes that warrants postpartum testing.

Plausible but not settled by a single definitive trial: the exact percentage reduction in malformation risk per unit change in HbA1c; the precise washout period required before conception for each specific GLP-1 agonist or SGLT2 inhibitor, which may change as labels are updated; whether one specific rapid-acting insulin analog produces meaningfully better outcomes than another for a given person.

Not established from the material available here: any individualized dose, timeline, or medication switch for a specific reader. Preconception diabetes management is highly dependent on diabetes type, duration, complication status, and prior pregnancy history, and requires an individualized plan from an endocrinologist and obstetric or maternal-fetal medicine team.

References

• American Diabetes Association Standards of Care (current annual edition), describes preconception and pregnancy glucose targets; verify the current-year edition with your care team.
• Centers for Disease Control and Prevention, Gestational Diabetes, https://www.cdc.gov/diabetes/data/gestational.html
• National Institute for Health and Care Excellence, Diabetes in pregnancy: management from preconception to the postnatal period (NICE NG3), https://www.ncbi.nlm.nih.gov/books/NBK552545/
• Postnatal experiences and perspectives on future pregnancies among women with type 1 diabetes: a qualitative study, https://pubmed.ncbi.nlm.nih.gov/42600402/
• Metabolic outcomes at 12 months postpartum among individuals with glucose intolerance in pregnancy, https://pubmed.ncbi.nlm.nih.gov/41628201/

Current FDA prescribing information for any specific insulin, metformin, GLP-1 agonist, or SGLT2 inhibitor product should be checked directly at fda.gov before making a medication decision, since labeling is updated over time and this article does not substitute for that check.